Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Eltrombopag
Drug ID BADD_D00759
Description Eltrombopag is used to treat low blood platelet counts in adults with chronic immune (idiopathic) thrombocytopenia (ITP), when certain other medicines, or surgery to remove the spleen, have not worked well enough. ITP is a condition that may cause unusual bruising or bleeding due to an abnormally low number of platelets in the blood. Eltrombopag has also been recently approved (late 2012) for the treatment of thrombocytopenia (low blood platelet counts) in patients with chronic hepatitis C to allow them to initiate and maintain interferon-based therapy.
Indications and Usage Thrombopoietin receptor agonists are pharmaceutical agents that stimulate platelet production in the bone marrow. In this, they differ from the previously discussed agents that act by attempting to curtail platelet destruction.
Marketing Status approved
ATC Code B02BX05
DrugBank ID DB06210
KEGG ID D03978
MeSH ID C520809
PubChem ID 135449332
TTD Drug ID D00PEH
NDC Product Code 47621-307
UNII S56D65XJ9G
Synonyms eltrombopag | Revolade | SB-497 115 | Promacta
Chemical Information
Molecular Formula C25H22N4O4
CAS Registry Number 496775-61-2
SMILES CC1=C(C=C(C=C1)N2C(=O)C(=C(N2)C)N=NC3=CC=CC(=C3O)C4=CC(=CC=C4)C(=O)O)C
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Myelodysplastic syndrome transformation16.01.04.005; 01.10.04.0050.000229%Not Available
Low birth weight baby18.04.02.0030.000229%Not Available
Oral disorder07.05.01.0050.001166%Not Available
Skin mass23.07.04.0140.000777%Not Available
Oropharyngeal pain22.12.03.016; 07.05.05.0040.003064%
Bone marrow reticulin fibrosis16.32.03.010; 01.05.01.0090.000686%Not Available
Autoimmune haemolytic anaemia01.06.01.004; 10.04.01.0050.000229%Not Available
Antiphospholipid syndrome18.02.04.002; 10.04.01.009; 01.01.02.016; 24.01.01.0290.000343%Not Available
Concomitant disease aggravated08.01.03.0630.000732%Not Available
Terminal state08.01.03.079--Not Available
Laziness19.04.04.005--Not Available
Breast cancer metastatic16.10.01.008; 21.05.01.0160.000229%Not Available
Renal embolism24.01.11.003; 20.01.07.0140.000229%Not Available
Spinal pain17.10.01.020; 15.02.01.008; 08.01.08.030--Not Available
Eye colour change06.06.06.0080.001555%Not Available
Internal haemorrhage24.07.01.0720.000457%Not Available
Cerebral venous sinus thrombosis24.01.04.021; 17.08.03.0060.000343%Not Available
Disease complication08.01.03.0870.000572%Not Available
Drug ineffective for unapproved indication12.09.02.002; 08.06.01.038--Not Available
Gait inability17.02.05.069; 08.01.02.0110.000457%Not Available
Illness08.01.03.0910.005396%Not Available
Immune thrombocytopenia01.08.01.013; 10.02.01.0830.002058%Not Available
Oral blood blister23.03.01.039; 12.01.17.016; 07.05.02.0040.000343%Not Available
Pharyngeal swelling22.04.05.0280.000503%Not Available
Physical deconditioning08.01.03.0960.000343%Not Available
Superficial vein thrombosis24.01.02.0160.001166%Not Available
Therapy non-responder08.06.01.0630.015524%Not Available
Therapy partial responder08.06.01.0640.000343%Not Available
Treatment noncompliance12.09.02.006; 08.06.01.067--Not Available
The 9th Page    First    Pre   9    Total 9 Pages